Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions.

The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases - 1 Jan 2000

Teixeira Rosângela, Nascimento Yone de Almeida, Crespo Déborah

Abstract excerpt

The standard of care therapy of chronic hepatitis C with the combination of pegylated interferon and ribavirin for 24 or 48 weeks was a remarkable accomplishment of the past decade. However, sustained virological responses rates of about 80% (genotypes 2-3) and 50% (genotype 1) were not satisfactory especially for patients infected with genotype 1. Important advances in the biology of HCV have made possible the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Interactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Oligopeptides

Share to Proline

Share to Protease Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 23490868
DOI: 10.1016/j.bjid.2012.10.010
PMCID: PMC9427372

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions.PMID 23490868Read ↗

Boceprevir: a recently approved protease inhibitor for hepatitis C virus infection.Semantic proximity Read ↗

Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.Semantic proximity Read ↗

How to optimize HCV therapy in genotype 1 patients: management of side-effects.Semantic proximity Read ↗

New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives.Semantic proximity Read ↗

Review of direct-acting antiviral agents for the treatment of chronic hepatitis C.Semantic proximity Read ↗

Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care.Semantic proximity Read ↗

Hepatitis C therapy update.Semantic proximity Read ↗

First-wave protease inhibitors for hepatitis C genotype 1 treatment: a real-life experience in Brazilian patients.Semantic proximity Read ↗

Dermatological adverse effects during genotype-1 hepatitis C treatment with the protease inhibitors telaprevir and boceprevir. Patient management.Semantic proximity Read ↗

Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET.Semantic proximity Read ↗

[New agents for the treatment of hepatitis C].Semantic proximity Read ↗

Update of the Belgian Association for the Study of the Liver guidelines for the treatment of chronic hepatitis C genotype 1 with protease inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.